Funding Announcement: MARAbio Raises $19 Million in Series A Round to Combat Maternal Autoantibody Related Autism

In a significant boost to its mission, MARAbio has raised $19 million in funding to advance its groundbreaking work in identifying the risk of Maternal Autoantibody Related Autism (MARA). This innovative company is at the forefront of autism research, focusing on a subtype that accounts for approximately 20% of all autism cases. MARAbio's unique risk assessment test is designed for prospective mothers prior to pregnancy, as well as for mothers during the early postnatal period, enabling families to take proactive steps in managing this complex condition. The newly acquired funds will be essential for further developing and refining their precision technology, which utilizes a simple blood test to detect a specific cluster of autoantibodies linked to MARA. With this test, mothers can receive the earliest possible risk assessment regarding their child's potential development of autism, thus providing families with options to materially reduce the occurrence or severity of the disorder. The investment will help propel MARAbio’s mission to transform how families approach autism risk and prevention, paving the way for broader clinical applications and ultimately fostering healthier, happier futures for children at risk. As MARAbio embarks on this pivotal journey, the commitment of investors demonstrates a shared belief in science and innovation as powerful tools to combat this pressing public health challenge.